- Trials with a EudraCT protocol (240)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
240 result(s) found for: Caregivers.
Displaying page 1 of 12.
EudraCT Number: 2021-006531-26 | Sponsor Protocol Number: 001-738 | Start Date*: 2023-05-14 |
Sponsor Name:Oslo University Hospital | ||
Full Title: A randomized, placebo-controlled, double-blind, 2-period cross-over study in youth with autism spectrum disorders evaluating social and repetitive behaviors after four weeks of twice daily-doses of... | ||
Medical condition: Autism spectrum disorders | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-008012-98 | Sponsor Protocol Number: sl2008-1 | Start Date*: 2009-12-18 |
Sponsor Name:Stefan Lundeberg | ||
Full Title: Pharmacokinetic study of the opioid ketobemidone in neonates after an intravenous administration | ||
Medical condition: Pain treatment with opioids in children | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000326-58 | Sponsor Protocol Number: ARC009 | Start Date*: 2018-09-27 | |||||||||||
Sponsor Name:Aimmune Therapeutics, Inc. | |||||||||||||
Full Title: Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adolescents: Real-World, Open-Label, Quality of Life Study | |||||||||||||
Medical condition: Peanut Allergy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) IE (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003087-27 | Sponsor Protocol Number: ARGX-113-2009 | Start Date*: 2022-09-26 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | |||||||||||||
Medical condition: Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) GR (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) HR (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003231-19 | Sponsor Protocol Number: ViRap | Start Date*: Information not available in EudraCT |
Sponsor Name:The Children's Memorial Health Institute | ||
Full Title: Randomized, placebo-controlled, double-blind and double-dummy clinical trial comparing the safety, tolerability, and efficacy of vigabatrin and rapamycin in a preventive treatment of infants with T... | ||
Medical condition: Tuberous Sclerosis Complex Epilepsy Tumors associated with Tuberous Sclerosis Complex | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-004548-64 | Sponsor Protocol Number: RaRETS | Start Date*: Information not available in EudraCT |
Sponsor Name:The Children's Memorial Health Institute | ||
Full Title: Multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of Rapamycin in drug Resistant Epilepsy associated with TSC (RaRE-TS) | ||
Medical condition: tuberous sclerosis complex, epilepsy, organ tumors associated with tuberous sclerosis | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005528-40 | Sponsor Protocol Number: EPISTOP | Start Date*: 2014-12-05 | |||||||||||
Sponsor Name:The Children's Memorial Health Institute | |||||||||||||
Full Title: Long-term, prospective study evaluating clinical and molecular biomarkers of epileptogenesis in a genetic model of epilepsy – Tuberous Sclerosis Complex. | |||||||||||||
Medical condition: Epilepsy in tuberous sclerosis complex (TSC) | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003536-12 | Sponsor Protocol Number: CIGE025B1301E1 | Start Date*: 2016-02-16 |
Sponsor Name:Novartis Pharmaceuticals | ||
Full Title: An Extension Study to CIGE025B1301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Omalizumab in Japanese Children (6 - 15 Years) With Inadequately Controlled Allergic Asthma Despite... | ||
Medical condition: Allergic Asthma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-004638-24 | Sponsor Protocol Number: SafePed01 | Start Date*: 2015-03-10 |
Sponsor Name:Ghent University Hospital | ||
Full Title: Pharmacokinetics of ciprofloxacine in pediatric patients, a pilot study – SAFE PEDRUG. | ||
Medical condition: febrile urinary tract infection | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-002287-14 | Sponsor Protocol Number: Reutelen | Start Date*: 2016-12-23 | |||||||||||
Sponsor Name:Erasmus MC Cancer Institute | |||||||||||||
Full Title: Death rattle in the dying phase: is prophylactic treatment useful? | |||||||||||||
Medical condition: Death rattle in the dying phase | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003832-54 | Sponsor Protocol Number: LUM001-303 | Start Date*: 2013-11-28 | |||||||||||
Sponsor Name:Mirum Pharmaceuticals, Inc. | |||||||||||||
Full Title: A MULTICENTRE EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND DURABILITY OF THE THERAPEUTIC EFFECT OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTI), IN THE TREATME... | |||||||||||||
Medical condition: Alagille syndrome (ALGS). This is an example of cholestatic liver disease in children. In patients with Alagille syndrome, impairment of the egress of bile acids from the liver leads to cholestasis... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023263-18 | Sponsor Protocol Number: A0081105 | Start Date*: 2013-06-12 | |||||||||||
Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 US | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES | |||||||||||||
Medical condition: Primary Generalised Tonic Clonic Seizures | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) HU (Completed) LT (Completed) NL (Completed) SK (Completed) AT (Completed) BG (Completed) ES (Completed) PL (Completed) EE (Completed) GR (Completed) BE (Completed) HR (Completed) DK (Completed) PT (Not Authorised) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004588-30 | Sponsor Protocol Number: D5180C00011 | Start Date*: 2019-06-05 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Multicenter, Randomized, Open-label, Parallel group, Functionality, and Performance Study of an Accessorized Pre-filled Syringe and Autoinjector with Home-administered Subcutaneous Tezepelumab i... | |||||||||||||
Medical condition: Severe uncontrolled asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000490-13 | Sponsor Protocol Number: EstuEla2022 | Start Date*: 2023-01-09 |
Sponsor Name:OILS4CURE S.L | ||
Full Title: Treatment, with a full spectrum extract of cannabis, in refractory epilepsy associated with tuberous sclerosis complex (TSC) | ||
Medical condition: Refractory epilepsy in tuberous sclerosis complex | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-000247-27 | Sponsor Protocol Number: ZX-2018-LBT999-DATTEP-3 | Start Date*: 2021-03-31 | ||||||||||||||||
Sponsor Name:ZIONEXA | ||||||||||||||||||
Full Title: Non-inferiority study of the molecular imaging of dopamine transporters using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to distinguish between Parkinson’s Disease and Essential Tremor. | ||||||||||||||||||
Medical condition: Patients suffering from an essential tremor or with Parkinson's disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002171-11 | Sponsor Protocol Number: 010622 | Start Date*: 2024-07-02 |
Sponsor Name:Medical University of Łódź | ||
Full Title: Randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of dimethyl fumarate in brain atrophy reduction, synaptic functional connectivity, cognitive functions, quality of ... | ||
Medical condition: dementia and mild cognitice impairment due to Alzheimer's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2021-006702-78 | Sponsor Protocol Number: BraimTOR-NEURO | Start Date*: Information not available in EudraCT |
Sponsor Name:The Children's Memorial Health Institute | ||
Full Title: Open, randomized, IInd phase clinical study evaluating the safety and efficacy of rapamycin in the treatment of drug-resistant epilepsy in children with rare and ultra-rare diseases of the central ... | ||
Medical condition: epilepsy, mTORopathies, focal cortical dysplasia, LEATS | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: PL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000379-96 | Sponsor Protocol Number: INnaloxonePed-1 | Start Date*: 2017-05-05 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Pharmacokinetic and pharmacodynamic aspects in children after intranasal administration of the opioid antagonist naloxone | ||
Medical condition: Pharmacokinetic profile after nasal naloxone administration in Children. In second part study reversal of sedation after opioid use | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001946-26 | Sponsor Protocol Number: AMITNED | Start Date*: 2016-01-19 |
Sponsor Name:Aarhus University Hospital | ||
Full Title: Amilorid treatment of nephrotic edema | ||
Medical condition: Childhood idiopathic nephrotic syndrome (NS) | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-005346-38 | Sponsor Protocol Number: LUM001-302 | Start Date*: 2013-06-11 | |||||||||||
Sponsor Name:Lumena Pharmaceuticals, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LUM001, AN APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITOR (ASBTi), IN THE TREATMENT OF CHOLESTAT... | |||||||||||||
Medical condition: Alagille syndrome (ALGS). This is an example of cholestatic liver disease in children. In patients with Alagille syndrome, impairment of the egress of bile acids from the liver leads to cholestasi... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
